Newellis Inc (NUWE) Quote

Once again the corrupt small hedge funds show up the next day on small stocks, that had run ups the past day, and turn on their grind down machines programs after they shorted the previous days highs, and profit off the scared little fliptards who sell out with their profits getting cut over night,if you want to beat the small wall street criminal hedge funds, you have to not be a wimp and sell out,and raise sell orders much higher,and let the scm bags get squeezed out of their corrupt short manipulation positions.

Im in at .15 - think Im gonna hold until .50... Not sure yet

Solid Day here, more to come...

Bought in at 0.18

Should test 0.30+

GhosT

holding until Monday EOD I think

Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology

May 02, 2024

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients suffering from fluid overload, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application related to its innovative pediatric Continuous Renal Replacement Therapy (CRRT) device branded Vivian™. This patent strengthens Nuwellis' intellectual property portfolio and paves the way for the development of novel technology designed to improve treatment options for critically ill children.
The patented technology focuses on a design feature that allows healthcare providers to switch seamlessly between stationary operation and “transport” or “ambulation” mode, enabling unprecedented patient mobility. This innovative feature offers unmatched flexibility, allowing clinicians to tailor treatment plans to the specific needs of each young patient.

"We are thrilled to receive this patent allowance from the USPTO," said Nestor Jaramillo, Jr., President and Chief Executive Officer of Nuwellis. “A core focus of our business strategy is developing novel technology and a strong IP portfolio. This innovative technology will empower healthcare providers with the ability to adapt treatment plans as needed, ultimately leading to improved patient care and outcomes for critically ill children and neonates.”

Nuwellis is currently developing a new, fully integrated pediatric continuous renal replacement therapy (CRRT) device designed to provide care for small babies and children. This development effort is funded in part by a $1.7 million grant from the National Institutes of Health (NIH). The company has partnered with Minneapolis-based research and development firm Koronis Biomedical Technologies Corporation (KBT), the grant recipient, in the design and development of a custom pediatric product that will enable clinicians to better care for babies with limited kidney function.

Nuwellis is committed to developing life-saving technologies specifically designed for the unique needs of pediatric patients. This patent allowance represents a significant advancement in the company's mission to revolutionize pediatric fluid management.

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or Twitter.

About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

https://ih.advfn.com/stock-market/NASDAQ/newellis-NUWE/stock-news/93767856/nuwellis-receives-uspto-notice-of-patent-allowance

$NUWE

I am holding for tomorrow

Flippers and profit takers. Ill guess 3 of these as this stedy climbs untill financials, guessing other news will follow the report

Guessing a better report than was anticipated??

Anyone have an exit price in mind??

hoping for a good report EOW

NICE PRE MARKET TRADING AND GOOD NEWS

Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology

Ill bite.... Im in

Whoops

NUWE new 52 lo

NUWE 10Q due March 5

As of today… NUWE has 5,000,000 shares of stock outstanding

Sounds good 1 hot toddy…

With today’s closing @.7011… NUWE is a BUY

man r they big spenders. employees get 764 shares each at option price of todays close 70 cents. vesting at 25% a year. only 3 mil shares issued but that can always change. few more days like today and all shares will be held.

NUWE is a HOLD @.5325…

WOOOOW 27000 SHARE BUY $$$$$$$$$$$$$

HELLO darlin'

12000 SHARE BUY RIGHT NOW $$$$$$$$$$$$$$$

16000 AND 10K SHARE BUY $$$$$$$$$$$$$$$$$$$$

@.69… NUWE is now listed as a HOLD

EGR… 19%

$NUWE > New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients

Nuwellis, Inc.
Tue, November 28, 2023 at 2:00 PM GMT+1

Recommendation Rating: Buy


Nuwellis, Inc.
The data demonstrate that the hematocrit sensor within the Nuwellis Aquadex® system offers unique advantages for fluid overloaded small patients

MINNEAPOLIS, Nov. 28, 2023 (GLOBE NEWSWIRE) -- New real-world data demonstrate that pediatric patients with fluid overload respond well to Aquadex® ultrafiltration therapy with continuous hematocrit monitoring, announced Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload. The publication, “Using Aquapheresis with Continuous Hematocrit Monitoring to Guide Ultrafiltration,” was featured in Pediatric Nephrology. 1

The publication is a single-center case study review of pediatric patients with hypoalbuminemia and severe fluid overload. Patients were treated with Nuwellis’ Aquadex® ultrafiltration therapy with continuous hematocrit monitoring to guide isotonic fluid removal. The study concluded that the therapy successfully treated small patients without hemodynamic instability or other complications, demonstrating that Aquadex is an effective treatment option for fluid overload.

“We’re proud to share new evidence supporting the clinical need and applications for Aquadex among pediatric patients, and we’re grateful to Dr. Michelle Starr and her colleagues for their trust and confidence in our therapy,” said Nestor Jaramillo, Jr., President and Chief Executive Officer of Nuwellis. “Our proprietary hematocrit sensor which is incorporated into the Aquadex console was a result of physician feedback and observations from clinical studies that drove us to make our Aquadex therapy even smarter. Our team is committed to supporting diuretic-resistant patients broadly, and I’m encouraged to see data validating this strategy as Nuwellis works to expand access to ultrafiltration to even more patients and clinicians.”

“Managing fluid overload for pediatric patients can be challenging, but these new data and our growing library of evidence support our view that Aquadex can provide a safe and effective method for restoring fluid balance,” said John Jefferies, MD, Chief Medical Officer of Nuwellis. “The continuous hematocrit monitoring function within the Aquadex provides unique and proprietary therapeutic direction, as demonstrated in this important publication.”

Effectively managing fluid overload for pediatric patients is critical. Fluid overload is associated with significant increases in mortality in pediatric patients. Research has shown that a 3% increase in mortality is observed for every 1% increase in fluid overload among these patients. 2,3

Aquadex is proven to simply, safely, and precisely remove excess fluid from patients suffering from fluid overload who have not responded to conventional medical management, including diuretics. Providers can specify and adjust the rate of fluid removed for each individual patient, resulting in a gradual reduction of excess fluid. The device’s built-in, customizable hematocrit monitoring technology provides real-time measurement of percent blood volume changes that can be tailored to individual patients’ needs. A customizable fluid removal rate is particularly important for pediatric patients, who have a small amount of blood in their bodies. The Aquadex system is cleared by the FDA for use in adults and pediatric patients weighing 20 kg (44 lbs.) or more.

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or Twitter.

About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.


CONTACTS:

Investors:
Vivian Cervantes
Gilmartin Group
ir@nuwellis.com

Media:
Laurel Hood
Health+Commerce
laurel@healthandcommerce.com

Link: https://finance.yahoo.com/news/real-world-data-highlight-clinical-130000845.html

$$$NUWE$$$

$NUWE ~ Nuwellis Inc
@0.65
+ 0.0227 (+3.62%)
Volume: 991,510
Day Range: 0.60 - 0.7658
Last Trade Time: 6:05:39 PM EST


$$$NUWE$$$

$NUWE >>> Know what you own! O/S @3.25M only.

https://www.nuwellis.com/corporate/

$NUWE >>> CTB @554.19%!

$NUWE took me a starter @.64! ;)


ULTRALOWFLOATER!! $$$$$$$

NUWE new 52 week low

EGR… 17%

NUWE new 52 week low

Could this be turning around now? Have we hit bottom? Pilot program with DaVita was supposed to begin by the end of the third quarter. Would love to see an update from $NUWE on this. Dipped my toes in @ $1.60. Any good news should move this back up over $2.

…the chart is looking promising

time to get greedy… ?

EGR is 22%… SG is 999%

looking like time to buy here...

Looks like we are starting to float…

EGR is improving… now @16% and SG also improves… now @42%. IMO… makes big moves higher come May.

Growth Rate 15% …Sales Growth 11% as of today

Almost time for the next leg up.

$NUWE trades as thin as ice, and with volume could absolutely go parabolic. 500K float. Squeeze time...imo.

This thing is starting to move… up 23% this week

Interesting to see a stock that trades 100% of its outstanding shares a day!! Never saw that before in all my years of watching stocks. Hmmm. I would not be surprised to see this make a parabolic move to the upside.

$NUWE is more than 2X undervalued…

$NUWE Mentioned in NEW Video!

I would love to see how many more Institutional Investors NUWE can get in 2023. 50%… should be the company benchmark IMHO.